The Investor
29 Oct 2025, 13:15
Thermo Fisher Scientific to Acquire Clario for $8.9 Billion to Boost Digital Clinical Capabilities
Thermo Fisher Scientific (NYSE: TMO) announced an agreement to acquire Clario Holdings, Inc., a leader in digital endpoint data solutions for clinical trials, for $8.875 billion in cash, with up to $400 million in performance-based earn-outs. The acquisition enhances Thermo Fisher’s data and AI-driven offerings for pharmaceutical and biotech clients, helping accelerate drug development and improve clinical insights.
Clario, which has supported around 70% of FDA drug approvals over the past decade, is expected to generate $1.25 billion in 2025 revenue. The deal is projected to be immediately accretive, adding $0.45 to adjusted EPS in the first year post-closing, with about $175 million in operating synergies anticipated within five years. The transaction is expected to close by mid-2026, pending regulatory approvals, and Clario will join Thermo Fisher’s Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE: TMO) announced an agreement to acquire Clario Holdings, Inc., a leader in digital endpoint data solutions for clinical trials, for $8.875 billion in cash, with up to $400 million in performance-based earn-outs. The acquisition enhances Thermo Fisher’s data and AI-driven offerings for pharmaceutical and biotech clients, helping accelerate drug development and improve clinical insights.
Clario, which has supported around 70% of FDA drug approvals over the past decade, is expected to generate $1.25 billion in 2025 revenue. The deal is projected to be immediately accretive, adding $0.45 to adjusted EPS in the first year post-closing, with about $175 million in operating synergies anticipated within five years. The transaction is expected to close by mid-2026, pending regulatory approvals, and Clario will join Thermo Fisher’s Laboratory Products and Biopharma Services segment.
